Brief Reports
Copyright ©The Author(s) 2005.
World J Gastroenterol. Aug 14, 2005; 11(30): 4735-4739
Published online Aug 14, 2005. doi: 10.3748/wjg.v11.i30.4735
Figure 1
Figure 1 PPARγ mRNA level. A: Expression of PPARγ mRNA. Lane 1, 10 µmol/L rosiglitazone group; lane 2, 3 µmol/L rosiglitazone group; lane 3, control group; B: Expression of β-actin.
Figure 2
Figure 2 PPARγ protein was assessed with Western blotting. Lane 1, 10 µmol/L rosiglitazone group; lane 2, 3 µmol/L rosiglitazone group; lane 3, control group.
Figure 3
Figure 3 Immunocytochemistry of rHSC-99 ×100. A: Positive of PPARγ in 10 µmol/L rosiglitazone group; B: positive of α-SMA in control group; C: weak positive of α-SMA in 10 µmol/L rosiglitazone group.